Clinical trials: Retinitis
X-Linked Retinitis Pigmentosa
Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
Phase 1 of the study is a dose escalation of the subretinal administration of AAV5-hRKp.RPGR vector to assess the safety of this vector in participants with XLRP caused by mutations in RPGR.
- Trial name
- NCT03252847
- Testing
- AAV5-RPGR
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 49 people
- Sponsor
- MeiraGTx UK II Ltd
Retinitis Pigmentosa
In Depth Observational Clinical Trial Of Retinitis Pigmentosa Patients
Typically, clinical research participation favors a specific demographic group, and little research exists on how trial attributes affect participation.
- Trial name
- NCT05849987
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Retinitis Pigmentosa
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia.
- Trial name
- NCT00447993
- Testing
- Low Dose NT-501, High Dose NT-501
- Where
- 11 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neurotech Pharmaceuticals
X-Linked Retinitis Pigmentosa
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.
- Trial name
- NCT06275620
- Testing
- AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Beacon Therapeutics
Retinitis Pigmentosa
Transcorneal Electrical Stimulation - Multicenter Safety Study
The purpose of this study is to expand the safety assessment of repeated applications of an electrical current from a DTL-like electrode in patients with RP.
- Trial name
- NCT01835002
- Testing
- Transcorneal electrostimulation
- Where
- 7 sites in Denmark, Germany and 1 more
- Volunteers
- 105 people
- Sponsor
- Okuvision GmbH
Retinitis Pigmentosa
Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)
The rod-cone dystrophies (often referred to as retinitis pigmentosa (RP)) are a clinically and genetically heterogeneous group of disorders in which there is progressive loss of rod and later cone photoreceptor function leading…
- Trial name
- NCT03349242
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- MeiraGTx UK II Ltd
Retinitis Pigmentosa
BS01 in Patients With Retinitis Pigmentosa
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
- Trial name
- NCT04278131
- Testing
- BS01
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bionic Sight LLC
Autoimmune Diseases, Ulcerative Colitis
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation.
- Conditions
- Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma
- Trial name
- NCT06587828
- Testing
- Companion blood samples with procedure
- Where
- 11 sites in United States
- Volunteers
- 238 people
- Sponsor
- TScan Therapeutics, Inc.
Retinitis Pigmentosa
Development of Visual Function Evaluation Method (2)
The objective of this study is to develop the comprehensive visual function evaluation method in severe visually impaired patient.
- Trial name
- NCT03626207
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Astellas Pharma Inc
Retinitis Pigmentosa
An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa
This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.
- Trial name
- NCT00661479
- Testing
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, 100 µg Brimonidine Tartrate Implant
- Where
- 4 sites in United States, France and 2 more
- Volunteers
- 21 people
- Sponsor
- Allergan
Non-syndromic Retinitis Pigmentosa
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
The objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light…
- Trial name
- PIONEER (NCT03326336)
- Testing
- Gene therapy: GS030-DP AND Medical device: GS030-MD
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 10 people
- Sponsor
- GenSight Biologics
X-Linked Retinitis Pigmentosa
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic X-linked retinitis pigmentosa (XLRP) due to…
- Trial name
- NCT04517149
- Testing
- 4D-125 IVT Injection, Observational
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- 4D Molecular Therapeutics
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Noninfectious Uveitis
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
- Trial name
- NCT00685399
- Testing
- AIN457, AIN 457
- Where
- 23 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
AMD - Age-Related Macular Degeneration, Retinitis Pigmentosa (RP)
Retinal Investigation Using Optos OCT Device
Retinal investigation using OCT with control and diseased eyes
- Conditions
- AMD - Age-Related Macular Degeneration, Retinitis Pigmentosa (RP), Diabetic Retinopathy, Control Patients
- Trial name
- NCT06846151
- Testing
- retinal functional imaging
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
X-Linked Retinitis Pigmentosa (XLRP)
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of…
- Trial name
- Landscape (NCT07174726)
- Testing
- Adeno-associated virus vector expressing a human RPGR gene
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Beacon Therapeutics
Retinitis Pigmentosa
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
The outcome of this trial will reveal the possibilities of the retinal implant to improve the situation of patients with hereditary retinal blindness caused by degenerations of the outer retina.
- Trial name
- NCT00515814
- Testing
- Retina implant is surgically placed into subretinal position
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Retina Implant AG
Retinitis Pigmentosa
Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa (adRP)
The purpose of this study is to gain an understanding of how adRP progresses over time in patients with misfolded rod opsin mutations.
- Trial name
- NCT02926092
- Testing
- Observation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Shire
Outer Retinal Degeneration, Retinitis Pigmentosa
Argus® II Retinal Prosthesis System Post-Market Surveillance Study
This post-market surveillance study is conducted in the European Economic Area where Argus II has been CE certified for use in outer retinal degeneration patients.
- Trial name
- NCT01490827
- Where
- 10 sites in Germany, Italy
- Volunteers
- 52 people
- Sponsor
- Second Sight Medical Products
Retinitis Pigmentosa, Choroideremia
Study of a Suprachoroidal Retinal Prosthesis
This study is a proof of principal, to evaluate a safety and efficacy of a prototype suprachoroidal retinal implant.
- Trial name
- NCT03406416
- Testing
- 44Ch Bionic Eye Device
- Where
- Australia
- Volunteers
- 4 people
- Sponsor
- Mobius Medical Pty Ltd.
Retinitis Pigmentosa
Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa
The purpose of this study is to evaluate the safety of intravitreal injection of autologous bone marrow stem cells in patients with retinitis pigmentosa by a prospective, single-center, randomized, parallel, double-blind, phase I…
- Trial name
- TC/RP (NCT02280135)
- Testing
- Intravitreal injection of Autologous bone marrow Stem Cell, Subconjunctival injection of saline
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Red de Terapia Celular